Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

REGEN-COV Antibody Cocktail in Outpatients with Covid-19

David M. Weinreich, Sumathi Sivapalasingam, Thomas Norton, Shazia Ali, Haitao Gao, Rafia Bhore, Andrea T. Hooper, Jennifer D. Hamilton, Bret J. Musser, Yuhwen Soo, Diana Rofail, Joseph Im, Christina Perry, Cynthia Pan, Romana Hosain, Adnan Mahmood, John D. Davis, Kenneth C. Turner, Alina Baum, Christos A. Kyratsous, Yunji Kim, Amanda Cook, Wendy Kampman, Ximena Graber, Gerard Acloque, Yessica Sachdeva, Joseph A. Bocchini, Anita Kohli, Bari Kowal, Thomas DiCioccio, Neil Stahl, Leah Lipsich, Ned Braunstein, Gary Herman, George D. Yancopoulos, for the Trial Investigators
doi: https://doi.org/10.1101/2021.06.09.21257915
David M. Weinreich
1Regeneron Pharmaceuticals, Inc., Tarrytown, NY
M.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: david.weinreich@regeneron.com
Sumathi Sivapalasingam
1Regeneron Pharmaceuticals, Inc., Tarrytown, NY
M.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas Norton
1Regeneron Pharmaceuticals, Inc., Tarrytown, NY
M.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shazia Ali
1Regeneron Pharmaceuticals, Inc., Tarrytown, NY
Pharm.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Haitao Gao
1Regeneron Pharmaceuticals, Inc., Tarrytown, NY
Ph.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rafia Bhore
1Regeneron Pharmaceuticals, Inc., Tarrytown, NY
Ph.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrea T. Hooper
1Regeneron Pharmaceuticals, Inc., Tarrytown, NY
Ph.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jennifer D. Hamilton
1Regeneron Pharmaceuticals, Inc., Tarrytown, NY
Ph.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bret J. Musser
1Regeneron Pharmaceuticals, Inc., Tarrytown, NY
Ph.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yuhwen Soo
1Regeneron Pharmaceuticals, Inc., Tarrytown, NY
Ph.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Diana Rofail
1Regeneron Pharmaceuticals, Inc., Tarrytown, NY
Ph.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joseph Im
1Regeneron Pharmaceuticals, Inc., Tarrytown, NY
B.S.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christina Perry
1Regeneron Pharmaceuticals, Inc., Tarrytown, NY
M.B.A.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cynthia Pan
1Regeneron Pharmaceuticals, Inc., Tarrytown, NY
B.Pharm.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Romana Hosain
1Regeneron Pharmaceuticals, Inc., Tarrytown, NY
M.D., M.P.H.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Adnan Mahmood
1Regeneron Pharmaceuticals, Inc., Tarrytown, NY
M.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John D. Davis
1Regeneron Pharmaceuticals, Inc., Tarrytown, NY
Ph.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kenneth C. Turner
1Regeneron Pharmaceuticals, Inc., Tarrytown, NY
Ph.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alina Baum
1Regeneron Pharmaceuticals, Inc., Tarrytown, NY
Ph.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christos A. Kyratsous
1Regeneron Pharmaceuticals, Inc., Tarrytown, NY
Ph.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yunji Kim
1Regeneron Pharmaceuticals, Inc., Tarrytown, NY
Pharm.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Amanda Cook
1Regeneron Pharmaceuticals, Inc., Tarrytown, NY
B.S., Dip.Reg.Aff.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wendy Kampman
1Regeneron Pharmaceuticals, Inc., Tarrytown, NY
M.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ximena Graber
2AGA Clinical Trials, Hialeah, FL
M.D., CPI, CCRP.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gerard Acloque
3Universal Medical and Research Center, LLC, Miami, FL
M.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yessica Sachdeva
4Arizona Liver Health, Chandler, AZ
M.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joseph A. Bocchini
5Willis-Knighton Physician Network, Shreveport, LA
M.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anita Kohli
6Arizona Liver Health, Tucson, AZ
M.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bari Kowal
1Regeneron Pharmaceuticals, Inc., Tarrytown, NY
M.S.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas DiCioccio
1Regeneron Pharmaceuticals, Inc., Tarrytown, NY
Ph.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Neil Stahl
1Regeneron Pharmaceuticals, Inc., Tarrytown, NY
Ph.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Leah Lipsich
1Regeneron Pharmaceuticals, Inc., Tarrytown, NY
Ph.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ned Braunstein
1Regeneron Pharmaceuticals, Inc., Tarrytown, NY
M.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gary Herman
1Regeneron Pharmaceuticals, Inc., Tarrytown, NY
M.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
George D. Yancopoulos
1Regeneron Pharmaceuticals, Inc., Tarrytown, NY
M.D., Ph.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Background REGEN-COV (casirivimab and imdevimab) antibody cocktail reduced SARS-CoV-2 viral load in descriptive analyses of the first 275 Covid-19 outpatients in the phase 1/2 portion of an ongoing double-blind, seamless phase 1/2/3 trial.

Methods This final analysis of the phase 1/2 portion includes 799 patients: 275 (group-1) and 524 (group-2). Patients were randomized (1:1:1) to placebo, 2400mg REGEN-COV, or 8000mg REGEN-COV, and characterized at baseline for endogenous immune response against SARS-CoV-2 (serum antibody-positive/negative). Efficacy was assessed in patients with a positive baseline RT-qPCR result; safety was assessed in all treated patients. Prespecified hierarchical analyses of virologic endpoints in group-2 were performed to confirm previously reported descriptive analyses from group-1. The proportion of patients with ≥1 Covid-19-related medically-attended visit (MAV) through day 29 was assessed in group-1+2.

Results Time-weighted average reduction in viral load (log10 copies/ml) through day 7 was significantly greater with REGEN-COV (combined 2400mg+8000mg dose groups) versus placebo in patients with baseline viral load >107 copies/ml (prespecified primary endpoint): -0.68 (95% CI, -0.94 to -0.41; P<0.0001). This reduction was -0.73 (P<0.0001) in serum antibody-negative patients and -0.36 (P=0.0003) in the overall population. Proportions of patients with ≥1 Covid-19-related MAV were 2.8% (12/434) with REGEN-COV versus 6.5% (15/231) with placebo (P=0.024; relative risk reduction=57%), with greater relative risk reductions in MAVs in patients with ≥1 risk factor for hospitalization (71%). Adverse events were similar across groups.

Conclusions REGEN-COV treatment of outpatients significantly reduced SARS-CoV-2 viral load and Covid-19-related medically-attended visits.

(Funded by Regeneron Pharmaceuticals and the Biomedical and Advanced Research and Development Authority of the Department of Health and Human Services; ClinicalTrials.gov number, NCT04425629.)

Competing Interest Statement

ICMJE disclosure forms provided by the authors are available with the full text of this article.

Clinical Trial

NCT04425629

Funding Statement

Supported by Regeneron Pharmaceuticals, Inc. Certain aspects of this project have been funded in whole or in part with federal funds from the Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority, under OT number: HHSO100201700020C.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Ethics approval was obtained from the following ethics review boards: WCG IRB, Puyallup, WA (IRB00000533); Providence St Joseph's Health, Renton, WA (STUDY2020000465); Research Compliance Office, Palo Alto, CA (IRB 5 Registration4593/Eprotocol: 57728).

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • The authors’ affiliations are as follows: Regeneron Pharmaceuticals (D.M.W., S.S., T.N., S.A., H.G., R.B., A.H., J.H., B.M., Y. Soo, D.R., J.I., C. Perry, C. Pan, R.H., A.M., J.D.D., K.C.T., A.B., C.K., Y.K., A.C., W.K., B.K., T.D., N.S., L.L., N.B., G.H., G.D.Y.), Tarrytown, NY; AGA Clinical Trials (X.G.), Hialeah, FL; Universal Medical and Research Center, LLC (G.A.), Miami, FL; Arizona Liver Health (Y. Sachdeva), Chandler, AZ; Willis-Knighton Physician Network (J.A.B), Shreveport, LA; and Arizona Liver Health (A.K.), Tucson, AZ.

Data Availability

Qualified researchers may request access to study documents (including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan) that support the methods and findings reported in this manuscript. Individual anonymized participant data will be considered for sharing once the indication has been approved by a regulatory body, if there is legal authority to share the data and there is not a reasonable likelihood of participant re-identification. Submit requests to https://vivli.org/.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted June 12, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
REGEN-COV Antibody Cocktail in Outpatients with Covid-19
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
REGEN-COV Antibody Cocktail in Outpatients with Covid-19
David M. Weinreich, Sumathi Sivapalasingam, Thomas Norton, Shazia Ali, Haitao Gao, Rafia Bhore, Andrea T. Hooper, Jennifer D. Hamilton, Bret J. Musser, Yuhwen Soo, Diana Rofail, Joseph Im, Christina Perry, Cynthia Pan, Romana Hosain, Adnan Mahmood, John D. Davis, Kenneth C. Turner, Alina Baum, Christos A. Kyratsous, Yunji Kim, Amanda Cook, Wendy Kampman, Ximena Graber, Gerard Acloque, Yessica Sachdeva, Joseph A. Bocchini, Anita Kohli, Bari Kowal, Thomas DiCioccio, Neil Stahl, Leah Lipsich, Ned Braunstein, Gary Herman, George D. Yancopoulos, for the Trial Investigators
medRxiv 2021.06.09.21257915; doi: https://doi.org/10.1101/2021.06.09.21257915
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
REGEN-COV Antibody Cocktail in Outpatients with Covid-19
David M. Weinreich, Sumathi Sivapalasingam, Thomas Norton, Shazia Ali, Haitao Gao, Rafia Bhore, Andrea T. Hooper, Jennifer D. Hamilton, Bret J. Musser, Yuhwen Soo, Diana Rofail, Joseph Im, Christina Perry, Cynthia Pan, Romana Hosain, Adnan Mahmood, John D. Davis, Kenneth C. Turner, Alina Baum, Christos A. Kyratsous, Yunji Kim, Amanda Cook, Wendy Kampman, Ximena Graber, Gerard Acloque, Yessica Sachdeva, Joseph A. Bocchini, Anita Kohli, Bari Kowal, Thomas DiCioccio, Neil Stahl, Leah Lipsich, Ned Braunstein, Gary Herman, George D. Yancopoulos, for the Trial Investigators
medRxiv 2021.06.09.21257915; doi: https://doi.org/10.1101/2021.06.09.21257915

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (269)
  • Allergy and Immunology (549)
  • Anesthesia (134)
  • Cardiovascular Medicine (1747)
  • Dentistry and Oral Medicine (238)
  • Dermatology (172)
  • Emergency Medicine (310)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (653)
  • Epidemiology (10780)
  • Forensic Medicine (8)
  • Gastroenterology (584)
  • Genetic and Genomic Medicine (2933)
  • Geriatric Medicine (286)
  • Health Economics (531)
  • Health Informatics (1918)
  • Health Policy (833)
  • Health Systems and Quality Improvement (743)
  • Hematology (290)
  • HIV/AIDS (627)
  • Infectious Diseases (except HIV/AIDS) (12496)
  • Intensive Care and Critical Care Medicine (684)
  • Medical Education (299)
  • Medical Ethics (86)
  • Nephrology (321)
  • Neurology (2780)
  • Nursing (150)
  • Nutrition (431)
  • Obstetrics and Gynecology (554)
  • Occupational and Environmental Health (597)
  • Oncology (1454)
  • Ophthalmology (440)
  • Orthopedics (172)
  • Otolaryngology (255)
  • Pain Medicine (190)
  • Palliative Medicine (56)
  • Pathology (379)
  • Pediatrics (865)
  • Pharmacology and Therapeutics (362)
  • Primary Care Research (333)
  • Psychiatry and Clinical Psychology (2630)
  • Public and Global Health (5338)
  • Radiology and Imaging (1002)
  • Rehabilitation Medicine and Physical Therapy (594)
  • Respiratory Medicine (722)
  • Rheumatology (329)
  • Sexual and Reproductive Health (288)
  • Sports Medicine (278)
  • Surgery (327)
  • Toxicology (47)
  • Transplantation (149)
  • Urology (125)